Optimizing serum adalimumab levels in maintenance therapy via proactive therapeutic drug monitoring improves markers of disease activity in Crohn’s disease
Proactive TDM-guided optimization of s-ADL levels in Crohn's disease patients on adalimumab maintenance therapy was associated with the modest but significant improvements in markers of disease activity over one year of follow-up.
Authors
- Knut E. A. Lundin (ORCID: https://orcid.org/0000-0003-1713-5545)
- Lars Aabakken (ORCID: https://orcid.org/0000-0002-3622-3826)
- Øyvind Steinsbø (ORCID: https://orcid.org/0000-0003-0004-0064)
- Tore Grimstad (ORCID: https://orcid.org/0000-0001-6669-5843)
- Arne Carlsen (ORCID: https://orcid.org/0000-0002-6005-6394)
- Nils Bolstad (ORCID: https://orcid.org/0000-0003-3633-8428)
- Roald Omdal (ORCID: https://orcid.org/0000-0002-6051-4658)
- Jan Terje Kvaløy (ORCID: https://orcid.org/0000-0002-8829-6250)
- David J. Warren (ORCID: https://orcid.org/0000-0001-6854-1282)
- Lars Karlsen
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Stavanger University Hospital (NO)
- University of Bergen (NO)
- University of Stavanger (NO)
Publication Details
- Journal
- Scandinavian Journal of Gastroenterology
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1080/00365521.2025.2573725
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00